In the PALOMA 3 trial, 4.7% of patients developed on-treatment RB1 mutations, indicating that CDK4/6 inhibitor therapy may provide selective pressure, leading to the development of Rb loss in a subset of breast cancer patients [140]. Here, CDK4 is linked to breast cancer.